MedTrace Logo

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

NCT05342493 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-03-21

No results posted yet for this study

Summary

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

Conditions

  • Migraine Disorders

Interventions

DRUG

Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yasuhiko Fukuta, PhD · Otsuka Pharmaceutical Co., Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-20
Primary Completion
2026-09-30
Completion
2029-06-22
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05342493 on ClinicalTrials.gov